SQZ Biotech partnership of $500M with Roche

SQZ Biotech formed a partnership with Roche in order to develop a cell therapy platform that would empower a patient’s own immune cells to fight a broad range of cancers. The agreement provides for over $500 million in upfront and potential clinical, regulatory and sales milestone-based payments for advancement of all products across all planned indications, in addition to royalties on potential future products. The proposed therapy involves using SQZ technology to introduce proteins into a patient’s B-cells which will then help activate killer T-cells to attack the cancer.

The ability to engineer such a response is fundamentally dependent on effective delivery of tumor-associated proteins, or antigens, into the patient’s B cells. This delivery process is uniquely enabled by SQZ’s technology and harnesses the power of the patient’s own immune system to fight tumors more effectively across a broad range of cancer types. It must be noted that SQZ Biotechnologies, which recently raised $5 million in a Series A funding, was spun out of MIT based on a scientific breakthrough by Dr. Armon Sharei, Prof. Klavs Jensen and Prof. Robert Langer.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More